Prochlorperazine: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 104: | Line 104: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:57, 20 March 2026
General
- Type: anti-psychotic and anti-emetic
- Dosage Forms: 5, 10
- Routes of Administration: IV, PO
- Common Trade Names: Compazine
Adult Dosing
Headache
- 10mg IV (slow push or in 1L IVF)
Nausea/Vomiting
- 5-10mg PO or IV q6-8 hours
- Max: 40mg/day
Pediatric Dosing
Nausea/vomiting, severe
2 yo and older, 9-14 kg
- 2.5mg PO q12-24 h; Max 7.5mg/day
2 yo and older, 14-18 kg
- 2.5mg PO q8-12 h; Max 10mg/day
2 yo and older, 18-39 kg
- 2.5mg PO q8 hr; Max 15mg/day
2 yo and older, >39 kg
- 5mg PO q6-8 h, Max: 20mg/day
Schizophrenia
2-5 yo
- 2.5 - 5mg PO q6-8 hr, Max 20mg/day
6-12 yo
- 2.5-5mg PO q6-8 hr, Max 25mg/day
Special Populations
- Pregnancy Rating: Pregnancy category C
- Lactation risk: Safety unknown
- Renal Dosing: not defined
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- tardive dyskinesia
- neuroleptic malignant syndrome
- blood dyscrasias
- agranulocytosis
- thrombocytopenic purpura
- orthostatic hypotension
- extrapyramidal symptoms
- cholestatic jaundice
- hepatotoxicity
- QT prolongation
- cardiac arrest
- seizures
- anaphylactoid reactions
- lupus erythematosus
- priapism
- heat stroke
- neonatal extrapyramidal symptoms (3rd trimester use)
- neonatal withdrawal symptoms (3rd trimester use)
Common
- Akathisia
- drowsiness
- dizziness
- blurred vision
- xerostomia
- constipation
- urinary retention
- headache
- nasal congestion
- nausea
- menstrual irregularities
- amenorrhea
- weight gain
- hyperprolactinemia
- hyperglycemia
- hypoglycemia
- insomnia
- agitation
- sexual dysfunction
- photosensitivity
- impaired body temperature regulation
Pharmacology
- Half-life: 3-5 hrs (oral); 7 hrs (IV)
- Metabolism: liver extensively, GI tract
- Excretion: urine, bile/feces
- Mechanism of Action: selectively antagonizes dopamine D2 receptors
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Headache | 10 mg IV | 1st line headache abortive | IV | Adult |
| Migraine headache | 10 mg IV | 1st line abortive (most effective) | IV | Adult |
| Migraine headache | 10 mg IV | 1st line headache abortive | IV | Adult |